Heel

Stonehenge may have aligned with the Moon as well as the Sun

Retrieved on: 
Friday, April 19, 2024

Six months later a smaller crowd congregates around the Heel stone to witness the midwinter Sun setting within the stone circle.

Key Points: 
  • Six months later a smaller crowd congregates around the Heel stone to witness the midwinter Sun setting within the stone circle.
  • But a hypothesis has been around for 60 years that part of Stonehenge also aligns with moonrise and moonset at what is called a major lunar standstill.
  • There is now an abundance of archaeological evidence that indicates the solar alignment was part of the architectural design of Stonehenge.

Lunar standstill

  • It is these longer sides that are thought to align with the major lunar standstill.
  • These southern and northern limits of moonrise (or set) change on a cycle of 18.6 years between a minimum and a maximum range – the so-called minor and major lunar standstills, respectively.
  • The major lunar standstill is a period of about one and a half to two years when the northernmost and southernmost moonrises (or sets) are furthest apart.
  • The strongest evidence we have for people marking the major lunar standstill comes from the US southwest.
  • Of six cutting dates, four correspond to major lunar standstill years between the years AD1018 and AD1093, indicating that the site was renewed, maintained or expanded on consecutive major standstills.
  • Returning to southern England, archaeologists think there is a connection between the major lunar standstill and the earliest construction phase of Stonehenge (3000-2500 BC), before the sarsen stones were brought in.
  • The major lunar standstill hypothesis, however, raises more questions than it answers.

A search for answers

  • It’s unclear whether the Moon would have been strong enough to cast shadows and how they would have interacted with the other stones.
  • This collaboration will result in events showcasing and debating the lunar alignments at both Stonehenge and at Chimney Rock.


Erica Ellingson receives funding from the US Department of Agriculture. This institution is an equal opportunity provider. Amanda Chadburn and Fabio Silva do not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and have disclosed no relevant affiliations beyond their academic appointment.

FullBloom Expands Leadership Team with Key Appointments

Retrieved on: 
Tuesday, April 9, 2024

She will plan and direct all aspects of the organization’s sales, including go-to-market strategy, new customer acquisitions, key account growth and overall pipeline management.

Key Points: 
  • She will plan and direct all aspects of the organization’s sales, including go-to-market strategy, new customer acquisitions, key account growth and overall pipeline management.
  • DeVore is an experienced healthcare services executive who worked in leadership roles spanning different sectors of healthcare and within organizations of various scale and structure.
  • The leadership team expansion comes on the heels of FullBloom’s acquisition of EmpowerU , a premier provider of evidence-based programs that improve student motivation, behaviors, and mental health.
  • Addressing the urgent mental health crisis facing America’s students is a top priority for FullBloom as it works to deliver critical services that support students academically, emotionally, and behaviorally.

Precision Neuroscience Names Verily Co-Founder Brian Otis as Chief Technology Officer

Retrieved on: 
Monday, April 8, 2024

NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Precision Neuroscience Corporation (Precision) today announced that Dr. Brian Otis has joined the company as Chief Technology Officer.

Key Points: 
  • NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Precision Neuroscience Corporation (Precision) today announced that Dr. Brian Otis has joined the company as Chief Technology Officer.
  • He was one of the co-founders of Verily, Alphabet Inc.’s healthcare and life sciences company, where he served as Chief Technical Officer and Fellow from 2015 through 2022.
  • He oversaw a large, multidisciplinary team in the end-to-end development of new medical technology, from discovery to manufacturing.
  • Under Otis’ technical leadership, Verily entered a number of significant collaborations with leading healthcare and pharmaceutical partners.

HAProxy Maintains Industry Leadership, Earns 97/100 Satisfaction Score in G2 Spring 2024 Grid® Reports

Retrieved on: 
Thursday, April 4, 2024

NEWTON, Mass., April 04, 2024 (GLOBE NEWSWIRE) -- HAProxy Technologies , the company behind the world’s fastest and most widely used software load balancer, has been named a Leader in 12 G2 Spring 2024 Reports.

Key Points: 
  • NEWTON, Mass., April 04, 2024 (GLOBE NEWSWIRE) -- HAProxy Technologies , the company behind the world’s fastest and most widely used software load balancer, has been named a Leader in 12 G2 Spring 2024 Reports.
  • Continuing to set the industry standard, HAProxy maintains overall leadership in Load Balancing as established in the previous three quarters.
  • With its highest-ever Satisfaction Score of 97, HAProxy was 40 points ahead of the second-placed leader in the Momentum Grid.
  • “We’re humbled by a near-perfect Satisfaction Score in the G2 Reports,” said Dujko Radovnikovic, CEO, HAProxy Technologies.

AITX’s RAD Offers SelectBlur at No Cost to Law Enforcement Agencies

Retrieved on: 
Tuesday, March 26, 2024

Detroit, Michigan, March 26, 2024 (GLOBE NEWSWIRE) -- Robotic Assistance Devices (RAD), a subsidiary of Artificial Intelligence Technology Solutions, Inc. (the “Company”) (OTCPK:AITX), is pleased to announce the availability of 'SelectBlur', to law enforcement agencies at zero cost1. This offers comes on the heels of widespread news stories of the Murrieta Police Department utilizing Lego images in an effort to obscure faces in booking photos and videos.

Key Points: 
  • “It’s our commitment to empower law enforcement with the most innovative technological solutions available,” said Steve Reinharz, CEO/CTO of AITX and RAD, reflecting on his deeply fulfilling years of collaboration with the LAPD.
  • The recent incident involving the Murrieta Police Department's utilization of Lego images to obscure faces in booking photos underscores the complexities law enforcement agencies face in adhering to evolving privacy regulations.
  • The California Legislature also passed Assembly Bill 1475 in 2021, prohibiting local law enforcement from publishing mug shots of suspects in nonviolent crimes.
  • By waiving the monthly subscription, RAD is now enabling law enforcement agencies to allocate their resources more efficiently, redirecting funds towards other critical needs such as training, equipment, or community outreach initiatives.

Holland America Line Becomes First Global Cruise Line to Receive International Seafood Certifications

Retrieved on: 
Monday, April 8, 2024

SEATTLE, April 8, 2024 /PRNewswire/ -- Holland America Line is elevating its award-winning dining experience by becoming the first global cruise line to receive both Marine Stewardship Council (MSC) and Aquaculture Stewardship Council (ASC) certifications. The two organizations serve as the most credible standards worldwide for certified seafood.

Key Points: 
  • SEATTLE, April 8, 2024 /PRNewswire/ -- Holland America Line is elevating its award-winning dining experience by becoming the first global cruise line to receive both Marine Stewardship Council (MSC) and Aquaculture Stewardship Council (ASC) certifications.
  • "Our guests care about the quality and sustainability of the fresh fish we serve, and so do we," said Gus Antorcha, president, Holland America Line.
  • Certified seafood from nine regions worldwide will be incorporated into Holland America Line seafood offerings: Asia, Australia, Canada/New England, Mexico, Mediterranean, Northern Europe, South America, the Caribbean, and Hawaii.
  • While not all seafood species aboard Holland America Line are currently certified, the cruise line is working toward 100% accreditation of species that are eligible to meet the organizations' standards.

FDA Grants Breakthrough Therapy Designation to Sunvozertinib for the First-Line Treatment of Patients with advanced Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations

Retrieved on: 
Sunday, April 7, 2024

SHANGHAI, April 7, 2024 /PRNewswire/ -- Dizal (688192.SH) today announced that the U.S. Food and Drug Administration ("FDA") has granted Breakthrough Therapy Designation (BTD) to its sunvozertinib as the first-line treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertion (Exon20ins) mutations.

Key Points: 
  • SHANGHAI, April 7, 2024 /PRNewswire/ -- Dizal (688192.SH) today announced that the U.S. Food and Drug Administration ("FDA") has granted Breakthrough Therapy Designation (BTD) to its sunvozertinib as the first-line treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertion (Exon20ins) mutations.
  • This Breakthrough Therapy Designation (BTD) approval was based on results from the global multi-center phase I/II study (WU-KONG1).
  • This new BTD will enable us work more closely with the FDA and accelerate its clinical development and regulatory submission."
  • Affecting roughly 2%-4% of NSCLC patients, EGFR Exon20ins mutations have been difficult to treat due to their unique spatial conformation, diverse mutation subtypes, and high heterogeneity.

Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory Diseases

Retrieved on: 
Monday, March 25, 2024

SAN FRANCISCO and WALTHAM, Mass., March 25, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis (AD), COPD, asthma and other inflammatory and immunology (I&I) indications, today announced that it has initiated dosing of healthy volunteers in its first clinical trial for APG808, a novel subcutaneous (SQ) extended half-life monoclonal antibody (mAb) targeting IL-4Rα, which is being developed as a treatment for people living with moderate-to-severe COPD, asthma and other I&I diseases.

Key Points: 
  • COPD is a progressive respiratory disease that is estimated to affect approximately 10 percent of the global population 40 years of age and older.
  • Despite recent advancements in COPD treatment, a significant number of people continue to suffer and die from the disease.
  • The APG808 Phase 1 trial is designed as a double-blind, placebo-controlled, first-in-human, single-ascending dose trial in healthy volunteers.
  • Importantly, this points to potentially less frequent dosing for patients with COPD, which could significantly improve quality of life.”

First in a Debut Series of Dark Action and Adventure Creates A Fantasy Story For The Ages

Retrieved on: 
Tuesday, March 19, 2024

The once tranquil and resplendent Kingdom of Alsteria has been ravaged by the indefinable darkness of those from the all-menacing Kingdom of Linia.

Key Points: 
  • The once tranquil and resplendent Kingdom of Alsteria has been ravaged by the indefinable darkness of those from the all-menacing Kingdom of Linia.
  • In a desperate attempt to save his crown and his people, Prince Christian of Alsteria turns to his last hope: Okhal.
  • But Okhal knows he’ll never follow customs and authority; he’s an outsider and savage who will not follow the customs of even God.
  • For more information about the author, please visit any of his social media platforms.

BioXcel Therapeutics Announces European Patent Office’s Grant of Patent for Method of Treating Agitation in Dementia Using Sublingual Dexmedetomidine

Retrieved on: 
Friday, March 15, 2024

The 486 patent covers the use of dexmedetomidine administered sublingually to treat agitation in individuals with dementia.

Key Points: 
  • The 486 patent covers the use of dexmedetomidine administered sublingually to treat agitation in individuals with dementia.
  • The patent encompasses a broad range of dosage forms, including films such as BXCL501 (sublingual dexmedetomidine), wafers, and tablets, at dexmedetomidine doses ranging from 3 mcg to 100 mcg.
  • 17/496,470 with claims pertaining to methods of treating agitation in patients with Alzheimer’s disease using the oromucosal administration of 60 mcg of dexmedetomidine in a water-soluble dosage form.
  • The patent, when issued, is expected to have an expiration date of July 17, 2040, subject to patent term adjustment, patent term extension, and terminal disclaimers.